Extracellular Vesicles and Their Role in Patients With Multiple Myeloma
Avatar

Biologically Based Therapies for MM: Surveying Novel Options

By Extracellular Vesicles and Their Role in Patients With Multiple Myeloma FEATURING Kenneth Anderson
August 3, 2021
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy and R…

26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Se…

10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Management of Multiple Myeloma: Smoldering Disease, Induction Therapy in T…

Feat. K. Shain
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can …

Feat. T. Martin
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
05:59
Sanofi

Racial Inequity in Autologous HCT Access in MM: Considering Incidence, Mor…

Feat. J. Mikhael
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therapy …

Feat. A. Rosko
13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

10:47
SOHO Highlights: State of the Art and Next Questions

Surveying the Induction and Maintenance Therapy Landscape in Newly Diagnos…

Feat. S. Lonial
09:14
Daniel Couriel

ASCO 2021 Highlights: Aspacytarabine in AML Patients & Ixazomib After …

05:54
Sanofi

Newly Diagnosed MM: Expert Analysis of Efficacy and Safety Outcomes of Aut…

Feat. L. Costa
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

14:57
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on HDT in Frontline MM: Is Lenalidomide, Bortezomib, …

Feat. A. Nooka
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…

Feat. E. Terpos
06:31
2nd SOHO Italian Conference

Treatment Options for the R/R MM Patients: A Review of the Current Data

Feat. K. Anderson
12:53
2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli
11:10
Yale Cancer Center

Yale Cancer Center Multiple Myeloma and Gammopathies: Translational Scienc…

Feat. N. Neparidze
05:58
Sanofi

Navigating the Role of Autologous HCT in Combination With Modern Induction…

Feat. J. Mikhael